Mosaic (MOS) Bets On Enzymes While Its Core Business Bleeds
This post was originally published on here On August 17, Mosaic Biosciences, a unit of The Mosaic Company (NYSE:MOS), launched Renuvis Enzara, an enzyme-based treatment meant to speed up how fast crop residue breaks down after harvest. The launch landed less than two weeks after Mosaic reported a second-quarter net loss of $273 million, a…








